SCHEMBL840697

SCHEMBL840697

CCCCC(=O)[N]C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482882 0.95
SCHEMBL9302132 0.92 CES2 (0.56)
SCHEMBL3281327 0.92 CES2 (0.56)
SCHEMBL76487 0.92 CES2 (0.56)
SCHEMBL4621525 0.92 CES2 (0.56)
SCHEMBL1679337 0.92 CES2 (0.56)
SCHEMBL5925480 0.92 CES2 (0.56)
SCHEMBL42694 0.85
SCHEMBL543757 0.82 CES1 (0.55)
SCHEMBL817806 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143408-B2 N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain ASTRAZENECA AB (SE) 2012-03-27 US claimed
US-20100137322-A1 NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2010-06-03 US claimed
EP-2158198-A2 NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN AstraZeneca AB (SE) 2010-03-03 EP claimed
WO-2008130320-A2 NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2008-10-30 WO claimed
EP-0673928-B1 Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists SANOFI SYNTHELABO (FR) 2001-08-29 EP claimed
EP-0321556-A4 USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM 1991-06-12 EP claimed
US-4880811-A SIDE EFFECT REDUCTION; NONSEDATING; GOUT; ANTIARTHRITIC AGENTS; METABOLIC, BLOOD AND GENETIC DISORDERS MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) 1989-11-14 US claimed
EP-0321556-A1 USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM Memorial Hospital for Cancer and Allied Diseases (US) 1989-06-28 EP claimed
WO-1988010114-A1 USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) 1988-12-29 WO claimed
CN-115667259-A Condensed ring compounds for inhibiting H-PGDS 佐藤制药株式会社 2023-01-31 CN disclosed
CN-104969406-A Electrolyte solution for electrochemical device and electrochemical device WAKO PURE CHEM IND LTD 2015-10-07 CN disclosed
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
EP-1932841-B1 SULFONAMIDE COMPOUND ASAHI KASEI PHARMA CORP (JP) 2014-01-01 EP disclosed
US-8415372-B2 Sulfonamide compound ASAHI KASEI PHARMA CORPORATION (JP) 2013-04-09 US disclosed
EP-0392317-A2 Benzimidazoles, drugs containing these compounds and process for their preparation Dr. Karl Thomae GmbH (DE) 1990-10-17 EP disclosed
US-4880811-A SIDE EFFECT REDUCTION; NONSEDATING; GOUT; ANTIARTHRITIC AGENTS; METABOLIC, BLOOD AND GENETIC DISORDERS MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) 1989-11-14 US disclosed
EP-0321556-A1 USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM Memorial Hospital for Cancer and Allied Diseases (US) 1989-06-28 EP disclosed
WO-1988010114-A1 USE OF C-5 MONO-SUBSTITUTED BARBITURATES TO TREAT DISORDERS OF URIC ACID METABOLISM MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) 1988-12-29 WO disclosed
US-4616015-A HYPOTENSIVE AGENT, ANTULCER AGENT, ANTICOAGULANT FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-10-07 US disclosed
EP-0122627-A2 Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-24 EP disclosed